Public call for individual patient data on treatment of rifampicin and multidrug-resistant (MDR/RR-TB) tuberculosis
16 February 2018, Geneva - In July 2018, the World Health Organization (WHO) will update its treatment guidelines for rifampicin and multidrug-resistant tuberculosis (MDR/RR-TB). Ahead of this meeting, WHO will commission reviews of relevant evidence on the effect of different treatment regimens on patient outcomes.
To enable this process, WHO is issuing a public call, appealing to industry, researchers, national TB programmes and other agencies to provide suitable datasets. The data will be essential to facilitate the process of WHO policy updates.
Please let us know if you have data to contribute by 01 March 2018. More information on the parameters of the datasets, variables, the process, deadlines and contacts is available by clicking here.
Further inquiries can be directed to the WHO Global TB Programme at LDR.POLICIES@WHO.INT